EcoDrugPlus

Endothelin Receptor Type B

Ensembl ID : ENSGFOG00000008106
Gene Symbol: EDNRB
1 Cross references
264 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSGFOG00000012383
Gene Symbol: EZH2
3 Cross references
222 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Epidermal Growth Factor Receptor

Ensembl ID : ENSGFOG00000006484
Gene Symbol: EGFR
1 Cross references
287 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSGFOG00000012241
Gene Symbol: ERBB4
1 Cross references
236 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Estrogen Receptor 1

Ensembl ID : ENSGFOG00000004320
Gene Symbol: ESR1
1 Cross references
213 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Estrogen Receptor 2

Ensembl ID : ENSGFOG00000000667
Gene Symbol: ESR2
3 Cross references
273 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Estrogen Related Receptor Gamma

Ensembl ID : ENSGFOG00000009952
Gene Symbol: ESRRG
3 Cross references
277 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Exportin 1

Ensembl ID : ENSGFOG00000003256
Gene Symbol: XPO1
3 Cross references
307 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Farnesyl Diphosphate Synthase

Ensembl ID : ENSGFOG00000009876
Gene Symbol: FDPS
1 Cross references
267 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Farnesyl-Diphosphate Farnesyltransferase 1

Ensembl ID : ENSGFOG00000001627
Gene Symbol: FDFT1
3 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSGFOG00000011262
Gene Symbol: FNTA
1 Cross references
221 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Fatty Acid Amide Hydrolase

Ensembl ID : ENSGFOG00000010792
Gene Symbol: FAAH
1 Cross references
131 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).